Key Developments: Allergan Inc (AGN)

AGN on New York Consolidated

186.80USD
24 Oct 2014
Price Change (% chg)

$3.43 (+1.87%)
Prev Close
$183.37
Open
$183.77
Day's High
$186.86
Day's Low
$183.26
Volume
463,561
Avg. Vol
2,319,964
52-wk High
$192.98
52-wk Low
$88.34

Search Stocks

Latest Key Developments (Source: Significant Developments)

Allergan announces OZURDEX receives european positive opinion for the treatment of Diabetic Macular Edema
Friday, 25 Jul 2014 07:55am EDT 

Allergan Inc:Says the European Union's Committee for Medicinal Products for Human Use (CHMP) has recommended extending the Marketing Authorization for OZURDEX ) (dexamethasone 700 mcg intravitreal implant in applicator) to treat adult patients with vision loss due to diabetic macular edema.CHMP is the scientific committee of the European Medicines Agency (EMA) that recommends medicines for Marketing Authorization across the 28 member states of the European Union.  Full Article

Allergan Inc raises FY 2014 outlook; gives FY 2015, 2016 EPS outlook above analysts' estimates; gives Q3 2014 outlook in line with analysts' estimates; gives charge outlook
Monday, 21 Jul 2014 08:00am EDT 

Allergan Inc:Sees FY 2014 EPS between $5.74 and $5.80.Sees FY 2015 EPS between $8.20 and $8.40.Sees FY 2016 EPS at about $10.00.Expects to incur total non-recurring pre-tax charges of between $375 and $425 million in connection with the restructuring and other costs.Sees FY 2014 total product net sales between $6.90 and $7.05 bln excluding any future anticipated revenue from the transition services agreements related to the sale of the obesity intervention business.Sees Q3 2014 total product net sales between $1.675 and $1.750 bln, excluding any future anticipated revenue from the transition services agreements related to the sale of the obesity intervention business.Sees Q3 2014 non-GAAP diluted earnings per share between $1.44 and $1.47.FY 2014 EPS $5.70 and revenue of $6.98 bln - Thomson Reuters I/B/E/S.FY 2015 EPS $6.85 - Thomson Reuters I/B/E/S.FY 2016 EPS $8.14 - Thomson Reuters I/B/E/S.Q3 2014 EPS $1.45 and revenue of $1.72 bln - Thomson Reuters I/B/E/S.  Full Article

Allergan declares second quarter dividend
Monday, 21 Jul 2014 08:00am EDT 

Allergan Inc:Declares second quarter dividend of $0.05 per share.Payable on Sept. 5 to stockholders of record on Aug. 15.  Full Article

Allergan Inc announces U.S. FDA approval
Monday, 30 Jun 2014 08:10am EDT 

Allergan Inc:Receives approval from U.S. Food and Drug Administration (FDA) for OZURDEX(reg)(dexamethasone intravitreal implant) 0.7 mg as treatment option for diabetic macular edema (DME) in adult patients who have an artificial lens implant (pseudophakic) or who are scheduled for cataract surgery (phakic).  Full Article

Valeant Pharmaceuticals International Inc commences exchange offer for Allergan Inc
Wednesday, 18 Jun 2014 09:30am EDT 

Allergan Inc:Says Valeant Pharmaceuticals International Inc announced that it has commenced an exchange offer for common stock of Allergan Inc.Under terms of offer, Allergan stockholders would be able to elect to exchange each of their Allergan shares for $72.00 in cash and 0.83 Valeant common shares, or an amount of cash, or number of Valeant common shares, in each case subject to proration.Valeant says amount of all cash and all stock elections would be determined prior to expiration of exchange offer.Offer is scheduled to expire at New York City time, on Aug. 15, 2014, unless offer is extended.Valeant expects to complete second-step merger promptly following consummation of exchange offer in order to acquire the remaining Allergan shares.  Full Article

Pershing Square Files lawsuit against Allergan Inc
Friday, 13 Jun 2014 06:00am EDT 

Allergan Inc:Pershing Square Capital Management, L.P. announced that an affiliate has filed a lawsuit in the Delaware Court of Chancery.Says it is seeking a declaratory judgment confirming that its actions in connection with the solicitation and receipt of revocable proxies to call a special meeting of shareholders of Allergan Inc.  Full Article

Valeant Pharmaceuticals International responds to Allergan 's rejection of merger proposal
Tuesday, 13 May 2014 08:01am EDT 

Valeant Pharmaceuticals International Inc:Says that it has responded to Allergan Inc.'s rejection of Valeant's proposal to combine with Allergan for $48.30 in cash and 0.83 shares of Valeant common stock for each Allergan share.Receives Allergan's letter rejecting Valeant's offer on May 12.  Full Article

Allergan Inc gives FY 2015 EPS outlook, gives long term outlook
Monday, 12 May 2014 07:00am EDT 

Allergan Inc:Expects to Increase EPS by 20 to 25 Percent in FY 2015 and by 20 Percent CAGR over next five years.FY 2015 EPS of $6.6 - Thomson Reuters I/B/E/S.  Full Article

Allergan Inc raises FY 2014 guidance; gives Q2 2014 guidance, EPS guidance above analysts' estimates
Wednesday, 7 May 2014 09:00am EDT 

Allergan Inc:Now expects FY 2014 total product net sales between $6.775 and $7.00 billion.FY 2014 non-GAAP diluted earnings per share attributable to stockholders between $5.64 and $5.73.FY 2014 revenue of $6.870 billion and EPS of $4.75 - Thomson Reuters I/B/E/S.Expects Q2 2014 total product net sales between $1.725 and $1.80 billion.Q2 2014 non-GAAP diluted earnings per share attributable to stockholders between $1.41 and $1.44.Q2 2014 revenue of $1.745 billion and EPS of $1.37 - Thomson Reuters I/B/E/S.  Full Article

Allergan Inc confirms receipt of unsolicited proposal from Valeant Pharmaceuticals International Inc
Tuesday, 22 Apr 2014 11:00am EDT 

Allergan Inc:Confirms that it has received an unsolicited proposal from Valeant Pharmaceuticals International, Inc to acquire all of the outstanding shares of the company for a combination of 0.83 of Valeant common shares and $48.30 in cash per share of common stock of the company.Says its board , in consultation with its financial and legal advisors, will carefully review and consider the proposal and pursue the course of action that it believes is in the best interests of the company's stockholders.Goldman, Sachs & Co. and BofA Merrill Lynch are serving as financial advisors to the company.Latham & Watkins is serving as legal counsel to the company.  Full Article

Stronger oil stocks and surge in Shire lift UK's FTSE

LONDON, Oct 21 - Gains in big oil companies and drugmaker Shire lifted Britain's top equity index on Tuesday, which extended a rebound after falling to 15-month lows last week.

Search Stocks